Endocrine Abstracts

Background: PD-L1 represents a novel class of drugs for treatment of a broad spectrum of malignancies including onco-hematologic diseases. This treatment is associated with several immuno-related adverse events (irAEs). Thyroid diseases and diabetes are among the most common PD-L1 endocrine-irAEs reported in solid cancers.Aims: To describe the frequency, the onset and the characteristics of PD-L1 endocrine-irAEs in patients with hematologic malignancies....

Background: In the last years, Pembrolizumab has been used to treat solid and lymphatic neoplasms, showing improved patients’ survival. Due to its mechanism of action, Pembrolizumab may be responsible of several immune-related adverse events (irAEs). The most frequent endocrine-irAEs reported are thyroid diseases.Aims: The aim of this study was to evaluate differences in thyroid disease incidence and presentation between patients treated for lung c...